Lv3
400 积分 2023-07-17 加入
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
2天前
已完结
Dual-pressure theory: new developments and future directions
1个月前
已完结
Targeting ARID1A: the key to dominating the differentiation fate of germinal center B cells
1个月前
已完结
Transcriptomic evidence from peripheral blood reveals nonlinear gene expression trajectories of aging in female rhesus macaques
1个月前
已完结
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
1个月前
已完结
Predict progression free survival and overall survival using objective response rate for anti—PD1/PDL1 therapy development
1个月前
已完结
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
2个月前
已完结
Computational approaches streamlining drug discovery
2个月前
已完结
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
2个月前
已完结
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
